6:20 PM
 | 
Dec 06, 2012
 |  BC Extra  |  Company News

Regulatory submissions on track for BioMarin's GALNS

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said during its R&D day on Thursday that it remains on track to submit regulatory applications next quarter in the U.S. and EU for Vimizim elosulfase alfa (formerly GALNS)...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >